Cantor Fitzgerald Comments on Cytokinetics FY2025 Earnings
Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Cytokinetics in a ...
Zacks.com on MSN20h
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study
Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure ...